2009 IoN News Archive
- Grant for research into new epilepsy treatments
- Professor Martin Rossor has been recognised by the The Alzheimer's Association
- Drug discovery collaboration on inclusion body myositis
- PDS awards Training Fellowship to Institute of Neurology researcher to understand how the brain controls Parkinson’s symptoms
- Alan Thompson to lead UCL Partners Neurological Disorders theme
- World MS Day - Wednesday 27th May - Global initiative to highlight Multiple Sclerosis
- Queen Square leads on new UK recommendations for bladder management which can dramatically improve quality of life in Multiple Sclerosis
- John Hardy most-cited Alzheimer's disease researcher in the UK
- Prestigious awards for Institute researchers
- Drug study offers hope for Alzheimer’s treatment
- Brain activity predicts our choices
- Professor George du Boulay CBE, FRCR, FRCP
- Brain awareness week: the impact of UCL research
- Parkinson's-linked mutation makes neurons vulnerable to calcium-induced death
- Second round of NIHR Senior Investigators announced
- 'Mind-Reading' Experiment Highlights How Brain Records Memories
- Anti-malaria drug does not appear to help with human prion diseases.
- UCL Partners is one of UK’s first Academic Health Science Centres
- "Opening doors for patients with MS"
- Are we as decisive as we think?
- "Magnets stop the nightmare of tinnitus, researchers say."
- Prestigious award for Professor Hugh Bostock
- Untangling the Brain
- Young UCL Investigator Award in neuroimaging techniques
- Brain disease "resistance gene" could offer insights into CJD
- Neurology: A Queen Square Textbook
- Headache: annual evidence update
- Roads closed for powerful MRI scanner delivery
- Long-term risks lower for surgical treatment of carotid stenosis
- Memorandum of collaboration signed
- Professor John Hardy joins the ranks of science greats
- Drug study offers hope for Alzheimer's treatment
- Prestigious award for Professor David Miller
- Magnets stop the nightmare of tinnitus, researchers say.
- Brain activity predicts our choices
- Jon Driver Award
- Professor Sander named recipient of the American Epilepsy Society 2009 Clinical Science Award
- Study highlights effect of brain waves on human behaviour
- New podcast describes the significance and impact of highly cited paper
- NIH Grant for research into inherited neuropathies
- How the brain knows a dog is a dog: concept acquisition in the human brain
- Prof Elizabeth Fisher elected member of the European Molecular Biology Organization (EMBO)
- Locating literacy in the brain
- Dopamine enhances expectation of pleasure in humans
- Queen Square scientists question memory theory
- IoN scientist to front Alzheimer’s Research Trust national appeal
- New doors open to the understanding of the origin of brain tumours
Model-based neuroanatomy: Testing hypotheses about white-matter connections in the living human brain
Published: Jun 20, 2013 2:30:00 PM
Published: Jul 2, 2013 4:00:00 PM
Published: Jul 5, 2013 4:15:00 PM
Published: Jul 8, 2013 9:00:00 AM
Anti-malaria drug does not appear to help with human prion diseases.
9 March 2009
Reported by Reuters -"The anti-malaria drug quinacrine does not appear to extend the lives of people with the human form of mad cow disease, despite encouraging results from experiments with mice, British researchers said on Tuesday. Their study of 107 volunteers showed some people who took the drug showed some improvement but that it was not possible to tell whether this was due to the medicine, researchers said.
The patients had Creutzfeldt-Jakob disease or CJD, a fatal brain-wasting illness in a family of diseases called prion diseases. These include mad cow disease or bovine spongiform encephalopathy, scrapie in sheep, and a new form of CJD that has infected fewer than 200 people worldwide who ate BSE-contaminated meat products.
"After adjusting for the substantial differences between patients who chose to take quinacrine or not, we did not find any evidence that oral quinacrine at a dose of 300 mg a day increased the length of survival of patients with prion disease," John Collinge of University College London (IoN Department of Neurodegenerative Disease & MRC Prion Unit) and colleagues wrote in the journal Lancet Neurology.
Currently there are no drugs that prevent or reverse the disease, though quinacrine has shown promise in treating prion-infected mouse cells because it can penetrate the blood-brain barrier, the researchers said...
"Future studies will need a design that provides unequivocal answers on treatment efficacy," he wrote in the Lancet Neurology. (Reporting by Michael Kahn, Editing by Maggie Fox and Jon Boyle).
read more >> Reuters
reference >> The
Lancet Neurology, 10 March 2009doi:10.1016/S1474-4422(09)70049-3